Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 15/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601450 | 0.81 | LMNA (0.64) | SMN1; SMN2LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL22601541 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAHSD17B10CNR2ALDH1A1 | |
| SCHEMBL22601545 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAHSD17B10CNR2ALDH1A1 | |
| SCHEMBL14868382 | 0.80 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL17207185 | 0.79 | SMN1; SMN2 (0.69) | SMN1; SMN2LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL22601453 | 0.79 | SMN1; SMN2 (0.69) | SMN1; SMN2LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL22601443 | 0.77 | HPGD (0.59) | SMN1; SMN2LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL22601430 | 0.77 | HPGD (0.59) | SMN1; SMN2LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL4739890 | 0.76 | CNR2 (0.60) | CNR2ALDH1A1F2PLGPRSS1 | |
| SCHEMBL22601522 | 0.75 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAHSD17B10ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | SMN1; SMN2 3406/4885LMNA 3233/4885HSD17B10 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.